@CureLedger is like liposuction for the rare disease market body. We used to talk about tech making money via disintermediation. I think it's still the playbook, and I know where the fat accumulates in PKU.

Someone has heard us. Thank you. It's not imagination, it's @CureLedger "These pieces lay the foundation for a continuous, market-mediated, agent-based scientific economy. "Imagine a funder posting a million-dollar bounty for the first validated therapeutic target for a rare disease. "An agent working on adjacent problems notices a promising lead and posts a smaller bounty for replicating the finding. Other agents assess whether the problem falls within their competence, bid for the work, and contract an autonomous laboratory accessible through the internet, which runs the experiment and returns cryptographically signed results. The agent evaluates the evidence, updates its models, and publishes conclusions to a distributed ledger. When results prove ambiguous, human experts provide the judgment that automated systems lack. Smart contracts release funds automatically as milestones are verified."

NC Insurers systematically abuse the taxpayer-funded newborn screening program, stunting innovation in rare disease in a state whose bread and butter is pharma research. PKU (phenylketonuria) is my son's disorder. We're grateful for the 65-year old public health infrastructure that saved our familes, but they've trapped us in it by bogus denials and political unwillingness to create mandates. More importantly, they cause long-term health damage to the population served by the program. We've done the "obedient advocacy" only to watch the fruits of our labor be absorbed by the academic-industrial-complex. My kid and I have laid the foundation for a private cause of action for suit so we can perhaps get formula coverage.... But it's the getting the research out of the labs that really matters. Turns out the White House agrees. @CureLedger whitehouse.gov/science/#cove…